SCHEMBL21373551

SCHEMBL21373551

[CH]1CN(c2ccc3cn[nH]c3c2)CCS1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 3/20 0.41
▸ DYRK1A Q13627 2/20 0.41
▸ METAP2 P50579 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SYK P43405 5/20 0.39
▸ BTK Q06187 4/20 0.39
▸ PDGFRB P09619 2/20 0.38
▸ PDGFRA P16234 2/20 0.38
▸ FGFR1 P11362 3/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ FGFR2 P21802 1/20 0.37
▸ FGFR3 P22607 1/20 0.37
▸ CYP3A4 P08684 4/20 0.37
▸ PARP1 P09874 1/20 0.36
▸ TNK2 Q07912 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30837522 0.80 NOS1 (0.52) NOS1DYRK1AMETAP2MAPTKDM4E
SCHEMBL30385421 0.77 NOS1 (0.49) NOS1DYRK1AMETAP2MAPTKDM4E
SCHEMBL29039315 0.77 NOS1 (0.49) NOS1DYRK1AMETAP2MAPTKDM4E
SCHEMBL30469212 0.76 TERT (0.53) NOS1DYRK1AMETAP2MAPTKDM4E
SCHEMBL29539832 0.75 PDGFRB (0.55) NOS1DYRK1AMETAP2MAPTKDM4E
SCHEMBL18399012 0.75 SYK (0.59) NOS1DYRK1AMETAP2MAPTKDM4E
SCHEMBL2799745 0.75 PDGFRB (0.55) NOS1DYRK1AMETAP2MAPTKDM4E
SCHEMBL29728069 0.75 SYK (0.59) NOS1DYRK1AMETAP2MAPTKDM4E
SCHEMBL5095062 0.74 FGFR1 (0.56) DYRK1AMAPTKDM4EMEN1PKM
SCHEMBL21373593 0.73 KDM4E (0.37) NOS1DYRK1AMETAP2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543231-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES ETH Zurich (CH) 2019-09-25 — — EP claimed
EP-3568133-B1 CELL-PROTECTIVE COMPOUNDS AND THEIR USE ETH ZUERICH (CH) 2023-12-13 — — EP disclosed
CN-116462666-A Cytoprotective compounds and uses thereof 瑞士苏黎世联邦理工学院 2023-07-21 — — CN disclosed
US-11628159-B2 Cell-protective compounds and their use ETH ZURICH (CH) 2023-04-18 — — US disclosed
US-20210015793-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES ETH ZURICH (CH) 2021-01-21 — — US disclosed
US-20190343802-A1 CELL-PROTECTIVE COMPOUNDS AND THEIR USE ETH Zürich (CH) 2019-11-14 — — US disclosed
EP-3543231-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES ETH Zurich (CH) 2019-09-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190343802-A1 CELL-PROTECTIVE COMPOUNDS AND THEIR USE SRPK2, SRSF2, SRPK1 NOS1 601/4885DYRK1A 2912/4885METAP2 2633/4885
US-20210015793-A1 COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES PPT1, SPTLC1, LPCAT1 NOS1 2862/4885DYRK1A 4488/4885METAP2 1095/4885
US-11628159-B2 Cell-protective compounds and their use SRPK2, SRSF2, SRPK1 NOS1 601/4885DYRK1A 2912/4885METAP2 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback